Craig-Hallum gives a buy rating to ADPT stock, citing growth potential and near-term catalysts

From Yahoo Finance: 2025-06-25 13:01:00

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) was rated a “Buy” by Craig-Hallum with a price target of $15, making it one of the 10 worst aggressive growth stocks to buy according to short sellers.

Adaptive Biotechnologies is a leader in testing to measure minimal residual disease in patients with hematologic malignancies, with a potential for sustainable 20%+ growth and near-term growth drivers.

The company’s clonoSEQ test can detect small quantities of cancer cells, aiding in treatment efficacy and identifying cancer recurrence earlier than other methods.

Near-term catalysts for ADPT include increased coverage, payor reimbursement rates, EMR integrations, and a strategic partnership with NeoGenomics.

ADPT is a commercial-stage biotechnology company focused on using the adaptive immune system to transform disease diagnosis and treatment.

While ADPT shows growth potential, other AI stocks may offer higher returns. Check out our report on the cheapest AI stock with 100x upside potential.



Read more at Yahoo Finance: Craig-Hallum Initiates Coverage of Adaptive Biotechnologies (ADPT) stock, Gives Buy